Analyst Price Target is GBX 1,462.50
▲ +8.74% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Abcam in the last 3 months. The average price target is GBX 1,462.50, with a high forecast of GBX 1,700 and a low forecast of GBX 1,250. The average price target represents a 8.74% upside from the last price of GBX 1,345.
Current Consensus is
The current consensus among 4 contributing investment analysts is to hold stock in Abcam. This Hold consensus rating has held steady for over two years.
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.